Table 1 Baseline Characteristics. Patients with primary combined endpoint versus transplant-free survivors (n = 68)

Age (yrs)

57 ± 8

59 ± 11

n.s.

Male (n)^a

13 (54%)

27 (61%)

n.s.

BMI (kg/m²)

25 (23-27)

25 (23-27)

n.s.

Heart rate (bpm)

78 ± 13

80 ± 14

n.s.

NYHA class

2 (2-3)

3 (2-3)

0.03

Karnofsky Index

85 ± 6

76 ± 10

0.0001

 MDRD (mL/min/1.73m²)

81 ± 17

83 ± 14

n.s.

 NT-proBNP (pg/mL)

1177 (528-3249)

3243 (1157-7505)

0.01

 cTNT ULN (n)^a

8 (38%)

18 (41%)

n.s.

 FLC difference (mg/dL)

1,1130 (435-5435)

3351 (975-8971)

n.s.

 AAPSE (mm)

8.8 (6.9-10.4)

6.1 (4.6-9.4)

0.02

 MAPSE anterior (mm)

8.1 (5.3-10.0)

6.2 (4.1-8.6)

n.s.

 MAPSE anterolateral (mm)

10.5 (8.1-13.4)

7.3 (5.4-11.7)

0.03

 MAPSE inferolateral (mm)

9.3 (6.3-12.1)

7.6 (5.2-12.2)

n.s.

 MAPSE inferior (mm)

9.2 (7.4-11.1)

8.0 (5.0-11.7)

n.s.

 MAPSE inferoseptal (mm)

7.6 (6.1-10.4)

7.1 (4.5-10.8)

n.s.

 TAPSE (mm)

18.0 (10.0-22.4)

14.1 (9.0-19.7)

n.s.

 GLS (%)

−14.8 ± 5.1

−13.2 ± 5.2

n.s.

 LS_basal (%)

−12.3 ± 6.1

−11.4 ± 8.5

n.s.

 LS_mid (%)

−16.4 ± 5.2

−14.7 ± 5.5

n.s.

 LS_apical (%)

−17.6 ± 5.9

−16.2 ± 6.6

n.s.

 Ejection Fraction (%)

62 ± 10

55 ± 13

0.03

 Septal wall (mm)

14 ± 5

13 ± 3

n.s.

 Lateral wall (mm)

10 ± 4

10 ± 4

n.s.

 Relative LV Mass (g/m²)

75 ± 21

73 ± 35

n.s.

 LA (mm)

39 ± 7

42 ± 7

n.s.

 Relative LGE (%)

16.5 (10.0-35.7)

25.0 (18.1-30.4)

n.s.

 Qualitative LGE (n)

2 (2-3)

2 (2-3)

n.s.